MSC-DNX-2401

DNX-2401 (Delta-24-RGD) oncolytic adenovirus delivered by mesenchymal stem cells

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MSC-DNX-2401, covering 2026-03-05 to 2026-03-05. Get the full timeline:

Most recent: Clinical Trial Update: MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma [Phase 1]